Marinus Pharmaceuticals Inc (MRNS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Marinus Pharmaceuticals Inc (MRNS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH141470D
  • |
  • Pages: 50
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Marinus Pharmaceuticals Inc (Marinus) is a clinical stage biopharmaceutical company that manufactures and commercializes therapeutics for the treatment of epilepsy, neuropsychiatric disorders and others diseases. The company's pipeline product comprise ganaxolone is a CNS-selective GABAA modulator, which has being developed in three different dose forms such as IV, capsule and liquid that is intended to maximize therapeutic reach to adult and pediatric patients in both acute and chronic care settings. Its Ganaxolone product has being evaluated in clinical trials for the treatment of pediatric genetic orphan epilepsies, behaviours in fragile x syndrome, and status epilepticus. Marinus is headquartered in Radnor, Pennsylvania, the US.

Marinus Pharmaceuticals Inc (MRNS)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Marinus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Marinus Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Marinus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Marinus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Marinus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Marinus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11

Venture Financing 11

Marinus Pharma Raises USD 21 Million In Series C Financing 11

Marinus Pharmaceuticals Raises USD11.43 in Venture Financing 13

Marinus Pharma Raises USD21.8 Million in Venture Financing 14

Licensing Agreements 15

Marinus Pharma Enters into Licensing Agreement with Ligand Pharma 15

CyDex Pharma Enters into Licensing Agreement with Marinus Pharma 16

Equity Offering 17

Marinus Pharma Plans to Raise up to USD200 Million in Public Offering of Securities 17

Marinus Pharma Raises USD40.3 Million in Public Offering of Shares 18

Marinus Pharma Raises USD30 Million in Public Offering of Shares 20

Marinus Pharma Files Registration Statement for Public Offering of Shares for up to USD35 Million 21

Marinus Pharma Completes IPO 22

Marinus Pharmaceuticals Inc-Key Competitors 24

Marinus Pharmaceuticals Inc-Key Employees 25

Marinus Pharmaceuticals Inc-Locations And Subsidiaries 26

Head Office 26

Recent Developments 27

Financial Announcements 27

Aug 02, 2018: Marinus Pharmaceuticals Provides Business Update and Second Quarter 2018 Financial Results 27

May 02, 2018: Marinus Pharmaceuticals Provides Business Update and First Quarter 2018 Financial Results 29

Mar 06, 2018: Marinus Pharmaceuticals Provides Business Update and 2017 Financial Results 30

Oct 31, 2017: Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2017 Financial Results 32

Aug 01, 2017: Marinus Pharmaceuticals Reports Second Quarter 2017 Financial Results 34

Mar 13, 2017: Marinus Pharmaceuticals Provides Business Update and 2016 Financial Results 35

Corporate Communications 36

Apr 11, 2017: Dr. Lorianne K. Masuoka Joins Marinus Pharmaceuticals as Chief Medical Officer 36

Feb 01, 2017: Marinus Appoints Michael R. Dougherty to its Board of Directors 37

Product Approvals 38

Jun 29, 2017: FDA Grants Orphan Drug Designation for Ganaxolone in CDKL5 Disorder 38

Jan 03, 2017: Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone to Treat Fragile X Syndrome 39

Clinical Trials 40

Sep 11, 2017: Marinus Announces Successful Clinical Trial Results and Declares CDKL5 Disorder Its Lead Pediatric Orphan Epilepsy Program for Ganaxolone 40

Aug 01, 2017: Marinus Pharmaceuticals Announces Update on Ganaxolone 42

Jun 27, 2017: Marinus Pharmaceuticals Launches the Ganaxolone Clinical Program in Patients with Postpartum Depression 43

Apr 18, 2017: Marinus to present Ganaxolone DATA at American academy of neurology annual meeting 44

Apr 10, 2017: Ganaxolone IV Clinical Data Presented at Leading International Status Epilepticus Medical Conference 45

Feb 14, 2017: Ganaxolone Reduces Seizures and Improves Behaviors in Angelman Syndrome Preclinical Model 46

Jan 23, 2017: Marinus Announces Positive Preliminary Data From Children With CDKL5 Genetic Disorder 47

Jan 05, 2017: Marinus Provides Business Outlook for 2017 48

Appendix 50

Methodology 50

About GlobalData 50

Contact Us 50

Disclaimer 50

List of Figures

Marinus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Marinus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Marinus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Marinus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Marinus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Marinus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Marinus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Marinus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

List of Tables

Marinus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Marinus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Marinus Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Marinus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Marinus Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Marinus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Marinus Pharma Raises USD 21 Million In Series C Financing 11

Marinus Pharmaceuticals Raises USD11.43 in Venture Financing 13

Marinus Pharma Raises USD21.8 Million in Venture Financing 14

Marinus Pharma Enters into Licensing Agreement with Ligand Pharma 15

CyDex Pharma Enters into Licensing Agreement with Marinus Pharma 16

Marinus Pharma Plans to Raise up to USD200 Million in Public Offering of Securities 17

Marinus Pharma Raises USD40.3 Million in Public Offering of Shares 18

Marinus Pharma Raises USD30 Million in Public Offering of Shares 20

Marinus Pharma Files Registration Statement for Public Offering of Shares for up to USD35 Million 21

Marinus Pharma Completes IPO 22

Marinus Pharmaceuticals Inc, Key Competitors 24

Marinus Pharmaceuticals Inc, Key Employees 25

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Marinus Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17835
Site License
USD 500 INR 35670
Corporate User License
USD 750 INR 53505

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com